Leptin as a cardiac pro-hypertrophic factor and its potential role in the development of heart failure

Current Pharmaceutical Design

Volumn 20, Issue 4, 2014, Pages 646-651

  Karmazyn, Morris ^a   Rajapurohitam, Venkatesh ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

Adipokines; Cardiac hypertrophy; Heart failure; Leptin

Indexed keywords

ANGIOTENSIN II; ENDOTHELIN 1; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; JANUS KINASE; LEPTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N(G) NITROARGININE METHYL ESTER; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP; PROTEIN TYROSINE PHOSPHATASE SHP 2; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STAT PROTEIN; STAT3 PROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CHRONOTROPISM; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE OXIDATION; HEART; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE WALL; HUMAN; HYPERLEPTINEMIA; INOTROPISM; INTRACELLULAR SIGNALING; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOVASCULAR SYSTEM; DISEASE PROGRESSION; HEART FAILURE; HUMANS; LEPTIN; MODELS, CARDIOVASCULAR; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION;

EID: 84894104988     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990023     Document Type: Article

References (75)

1. Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006; 29: 81-90
2. Purdham DM, Zou MX, Rajapurohitam V, Karmazyn M. Rat heart is a site of leptin production and action. Am J Physiol Heart Circ Physiol 2004; 287: H2877-84.
3. Rajapurohitam V, Javadov S, Purdham DM, Kirshenbaum LA, Karmazyn M. An autocrine role for leptin in mediating the cardiomyocyte hypertrophic effects of angiotensin II and endothelin-1. J Mol Cell Cardiol 2006; 41: 265-74.
4. Nickola MW, Wold LE, Colligan PB, Wang GJ, Samson WK, Ren J. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role of NO. Hypertension 2000; 36: 501-5.
5. Sinha MK, Opentanova I, Ohannesian JP, et al. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. J Clin Invest 1996; 98: 1277-82.
6. Myers MG Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent Prog Horm Res 2004; 59: 287-304.
7. Lee GH, Proenca R, Montez JM, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-5.
8. Wold LE, Relling DP, Duan J, Norby FL, Ren J. Abrogated leptininduced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 2002; 39: 69-74.
9. Löllmann B, Grüninger S, Stricker-Krongrad A, Chiesi M. Detection and quantification of the leptin receptor splice variants Ob-Ra, b, and, e in different mouse tissues. Biochem Biophys Res Commun 1997; 238: 648-52.
10. Ge H, Huang L, Pourbahrami T, Li C. Generation of soluble leptin receptor by ectodomain. shedding of membrane-spanning receptors in vitro and in vivo. J Biol Chem 2002; 277: 45898-903.
11. Maamra M, Bidlingmaier M, Postel-Vinay MC, Wu Z, Strasburger CJ, Ross RJ. Generationof human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology 2001; 142: 4389-93.
12. Bjørbaek C, Buchholz RM, Davis SM, et al. Divergent roles of SHP-2 in ERK activation by leptin receptors. J Biol Chem 2001; 276: 4747-55.
13. Knudson JD, Dincer UD, Zhang C, et al. Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005; 289: H48-56.
14. Hintz KK, Aberle NS, Ren J. Insulin resistance induces hyperleptinemia, cardiac contractile dysfunction but not cardiac leptin resistance in ventricular myocytes. Int J Obes Relat Metab Disord 2003; 27: 1196-203.
15. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl CoA axis. J Biol Chem 2002; 277: 29424-30.
16. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003; 93: 277-9.
17. Abe Y, Ono K, Kawamura T, et al. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 2007; 292: H2387-96.
18. Xu FP, Chen MS, Wang YZ, et al. Leptin induces hypertrophy via endothelin-1-1reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 2004; 110: 1269-75.
19. Barton M, Carmona R, Ortmann J, Krieger JE, Traupe T. Obesityassociated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003; 35: 826-37.
20. Tajmir P, Ceddia RB, Li RK, Coe IR, Sweeney G. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase-and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 145: 1550-5.
21. Madani S, De Girolamo S, Muñoz DM, Li RK, Sweeney G. Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes. Cardiovasc Res 2006; 69: 716-25.
22. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-9.
23. Purdham DM, Rajapurohitam V, Zeidan A, Huang C, Gross GJ, Karmazyn M. A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heart. Am J Physiol Heart Circ Physiol; 295: H441-6.
24. Moro C, Grauzam S, Ormezzano O, et al. Inhibition of cardiac leptin expression after infarction reduces subsequent dysfunction. J Cell Mol Med 2011; 15: 1688-94.
25. McGaffin KR, Witham WG, Yester KA, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res 2011; 89: 60-71.
26. Hegyi K, Fülöp K, Kovács K, Tóth S, Falus A. Leptin-induced signal transduction pathways. Cell Biol Int 2004; 28: 159-69.
27. Zabeau L, Lavens D, Peelman F, Eyckerman S, Vandekerckhove J, Tavernier J. The ins and outs of leptin receptor activation. FEBS Lett 2003; 546: 45-50.
28. Ahima RS, Osei SY. Leptin signaling. Physiol Behav 2004; 81: 223-41.
29. McGaffin KR, Moravec CS, McTiernan CF. Leptin signaling in the failing and mechanically unloaded human heart. Circ Heart Fail 2009; 2: 676-83.
30. Fonfara S, Hetzel U, Tew SR, Dukes-McEwan J, Cripps P, Clegg PD. Leptin expression in dogs with cardiac disease and congestive heart failure. J Vet Intern Med 2011; 25: 1017-24.
31. Na T, Dai DZ, Tang XY, Dai Y. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 39-49.
32. Bjørbaek C, Uotani S, da Silva B, Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem 1997; 272: 32686-95.
33. Uotani S, Bjørbaek C, Tornøe J, Flier JS. Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999; 48: 279-86.
34. Akasaka Y, Tsunoda M, Ogata T, Ide T, Murakami K. Direct evidence for leptin-induced lipid oxidation independent of long-form leptin receptor. Biochim Biophys Acta 2010; 1801: 1115-22.
35. Kloek C, Haq AK, Dunn SL, Lavery HJ, Banks AS, Myers MG Jr. Regulation of Jak kinases by intracellular leptin receptor sequences. J Biol Chem 2002; 277: 41547-55.
36. Banks AS, Davis SM, Bates SH, Myers MG J. Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000; 275: 14563-72.
37. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2002; 2: 497-503.
38. Kaszubska W, Falls HD, Schaefer VG, et al. Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line. Mol Cell Endocrinol 2002; 195: 109-18.
39. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2: 489-95.
40. Baumann H, Morella KK, White DW, et al. The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA 1996; 93: 8374-8.
41. Bendinelli P, Maroni P, Pecori Giraldi F, Piccoletti R. Leptin activates Stat3, Stat1 and AP-1 in mouse adipose tissue. Mol Cell Endocrinol 2000; 168: 11-20.
42. Briscoe CP, Hanif S, Arch JR, Tadayyon M. Fatty acids inhibit leptin signalling in BRIN-BD11 insulinoma cells. J Mol Endocrinol 2001; 26: 145-54.
43. Heim MH. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus. Eur J Clin Invest 1996; 26: 1-12.
44. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997; 278: 1803-5.
45. van den Brink GR, O'Toole T, Hardwick JC, et al. Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen-activated protein (MAP) kinase and p70 S6 kinase. Mol Cell Biol Res Commun 2000; 4: 144-50.
46. Bouloumié A, Drexler HC, Lafontan M, Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ Res 1998; 83: 1059-66.
47. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer celladipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-7.
48. Shin EJ, Schram K, Zheng XL, Sweeney G. Leptin attenuates hypoxia/ reoxygenation-induced activation of the intrinsic pathway of apoptosis in rat H9c2 cells. J Cell Physiol 2009; 221: 490-7.
49. McGaffin KR, Zou B, McTiernan CF, O'Donnell CP. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res 2009; 83: 313-24.
50. Sharma V, Mustafa S, Patel N, Wambolt R, Allard MF, McNeill JH. Stimulation of cardiac fatty acid oxidation by leptin is mediated by a nitric oxide-p38 MAPK-dependent mechanism. Eur J Pharmacol 2009; 617: 113-7.
51. Loirand G, Guérin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-34
52. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006; 290: C661-8.
53. Zeidan A, Javadov S, Karmazyn M. Essential role of Rho/ROCKdependent processes and actin dynamics in mediating leptininduced hypertrophy in rat neonatal ventricular myocytes. Cardiovasc Res 2006; 72: 101-11.
54. Zeidan A, Hunter JC, Javadov S, Karmazyn M. mTOR mediates RhoA-dependent leptin-induced cardiomyocyte hypertrophy. Mol Cell Biochem 2011; 352: 99-108.
55. Moey M, Rajapurohitam V, Zeidan A, Karmazyn M. Ginseng (Panax quinquefolius) attenuates leptin-induced cardiac hypertrophy through inhibition of p115Rho guanine nucleotide exchange factor-RhoA/Rho-associated, coiled-coil containing protein kinasedependent mitogen-activated protein kinase pathway activation. J Pharmacol Exp Ther 2011; 339: 746-56.
56. Zeidan A, Javadov S, Chakrabarti S, Karmazyn M. Leptin-induced cardiomyocyte hypertrophy involves selective caveolae and RhoA/ROCK-dependent p38 MAPK translocation to nuclei. Cardiovasc Res 2008; 77: 64-72.
57. Schulze PC, Biolo A, Gopal D, et al. Dynamics in insulin resistance and plasma levels of adipokines in patients with acute decompensated and chronic stable heart failure. J Card Fail 2011; 17: 1004-11.
58. Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003; 5: 33-40.
59. Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. Int J Cardiol 2002; 83: 73-81.
60. Patel JV, Sosin M, Lim HS, et al. Raised leptin concentrations among South Asian patients with chronic heart failure. Int J Cardiol 2007; 122: 34-40.
61. Lieb W, Sullivan LM, Harris TB, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals. Diabetes Care 2009; 32: 612-6.
62. Abd El-Aziz TA, Mohamed RH, Mohamed RH, Pasha HF. Leptin, leptin gene and leptin receptor gene polymorphism in heart failure with preserved ejection fraction. Heart Vessels 2011 [Epub ahead of print]
63. Gupta S, Drazner MH, de Lemos JA. Newer biomarkers in heart failure. Heart Fail Clin 2009; 5: 579-88.
64. Schulze PC, Kratzsch J. Leptin as a new diagnostic tool in chronic heart failure. Clin Chim Acta 2005; 362: 1-11.
65. Yanavitski M, Givertz MM. Novel biomarkers in acute heart failure. Curr Heart Fail Rep 2011; 8: 206-11.
66. Straburzyńska-Migaj E, Gwizdała A, Siniawski A, Ochotny R, Grajek S. Leptin and inflammation in patients with chronic heart failure. Kardiol Pol 2010; 68: 1243-7.
67. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Obesity and risk of incident heart failure in older men with and without pre-existing coronary heart disease: does leptin have a role? J Am Coll Cardiol 2011; 58: 1870-7.
68. Deswal A. Obesity, leptin, and incident heart failure. J Am Coll Cardiol 2011; 58: 1878-80.
69. Toth MJ, Gottlieb SS, Fisher ML, Ryan AS, Nicklas BJ, Poehlman ET. Plasma leptin concentrations and energy expenditure in heart failure patients. Metabolism 1997; 46: 450-3.
70. Murdoch DR, Rooney E, Dargie HJ, Shapiro D, Morton JJ, McMurray JJ. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure. Heart 1999; 82: 352-6.
71. Filippatos GS, Tsilias K, Venetsanou K, et al. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-α system. Int J Cardiol 2000; 76: 117-22.
72. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 2008; 88: 389-419.
73. Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008; 79: 279-86.
74. Park M, Sweeney G. Direct effects of adipokines on the heart: focus on adiponectin. Heart Fail Rev. 2012 Aug 15. [Epub ahead of print]
75. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol 2012; 165: 574-590.